<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21540">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01700712</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2010-112</org_study_id>
    <nct_id>NCT01700712</nct_id>
  </id_info>
  <brief_title>Acid Production in Dental Plaque After Exposure to Probiotic Bacteria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Calcin foundation, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <authority>Denmark:Danish Ethical Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The increasing interest in probiotic lactobacilli in health maintenance has raised the
      question of potential risks. One possible side effect could be an increased acidogenicity in
      dental plaque. The aim of this study was to investigate the effect of probiotic lactobacilli
      on plaque lactic acid (LA) production in vitro and in vivo.

      Methods. subjects (n=18) were given lozenges with probiotic lactobacilli (L. reuteri DSM
      17938 and ATCC PTA 5289) or placebo for two weeks in a double-blinded, randomized cross-over
      trial. The concentration of LA in supragingival plaque samples was determined at baseline
      and after 2 weeks. Salivary counts of mutans streptococci (MS) and lactobacilli were
      estimated with chair-side methods.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Acid production in plaque after exposure to probiotic bacteria</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acid producton in plaque after in vitro exposure to probiotic bacteria</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Caries</condition>
  <arm_group>
    <arm_group_label>L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 tablets a day for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets a day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic Lactobacilli reuteri</intervention_name>
    <arm_group_label>L. reuteri (DSM 17938 and ATCC PTA 5289; 1x108 CFU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to high counts of salivary mutans streptococci (&gt;104 CFU) as estimated with
             the Dentocult SM chair-side test,

          -  no visible open caries lesions or periodontal disease,

        Exclusion Criteria:

          -  smokers,

          -  ingestion of probiotic bacteria within the last two months,

          -  ingestion of antibiotics within the last two months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette K Keller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 3, 2012</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Mette Kirstine Keller</investigator_full_name>
    <investigator_title>Reasearch Associate</investigator_title>
  </responsible_party>
  <keyword>Caries, probiotic bacteria</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
